title: Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype.
abstract: T-cell prolymphocytic leukemia (T-PLL) is a rare postthymic T-cell disorder. The disease is characterized by lymphadenopathy, splenomegaly, skin lesions, a high white blood cell count, and an aggressive clinical course. The small cell variant of T-PLL occurs in approximately 20% of patients. Most T-PLL patients express membrane T-cell receptors (TCR) of the alphabeta phenotype. The diagnosis of small cell variant T-PLL in a 56-year-old woman was based on the findings of abnormal lymphocytosis, immunophenotype, lymphadenopathy, and aggressive clinical behavior. Immunophenotype analysis showed that lymphocytes were positive for CD2, CD3, CD5, CD7, CD8, and TCR gammadelta antigens and negative for CD1a, CD4, and TCR alphabeta antigens. Southern blot analysis revealed rearrangement of the TCR Jgamma and Jdelta-1 genes. A cytogenetic study of peripheral blood showed a normal karyotype. T-PLL with a TCR gammadelta phenotype is very rare. This case was typical T-PLL except for the morphologically small cell type and the lack of the typical chromosome aberration. If cases accumulate in the future, the specific features of the gamma8 type of T-PLL will become clearer.
authors.affiliation: Department of Internal Medicine, Yokosuka Kyousai Hospital, Kanagawa, Japan. s-toyota@ykh.gr.jp
authors.forename: Shigeo
authors.initials: S
authors.lastname: Toyota
authors.forename: Norihiko
authors.initials: N
authors.lastname: Nakamura
authors.forename: Kazuo
authors.initials: K
authors.lastname: Dan
mesh_terms: D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015463:Leukemia, Prolymphocytic / Q000473:pathology* / Q000628:therapy; D015458:Leukemia, T-Cell / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000378:metabolism*; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology
chemical_list: D016692:Receptors, Antigen, T-Cell, gamma-delta
references.citation: J Clin Oncol. 2001 Apr 15;19(8):2142-52
references.pmid: 11304766
references.citation: Blood. 2001 Sep 15;98(6):1721-6
references.pmid: 11535503
references.citation: Ann Hematol. 2001 Dec;80(12):749-51
references.pmid: 11797117
references.citation: Ann Oncol. 2002 Nov;13(11):1792-8
references.pmid: 12419753
references.citation: J Exp Med. 1989 Apr 1;169(4):1277-94
references.pmid: 2564416
references.citation: Br J Haematol. 1986 Sep;64(1):111-24
references.pmid: 3489482
references.citation: Am J Pathol. 1988 Sep;132(3):401-5
references.pmid: 3261945
references.citation: Blood. 1991 Dec 15;78(12):3269-74
references.pmid: 1742486
references.citation: Am J Pathol. 1990 Sep;137(3):617-28
references.pmid: 1698028
references.citation: Br J Haematol. 1998 Jun;101(4):753-5
references.pmid: 9674751
references.citation: Blood. 2004 Jul 15;104(2):328-35
references.pmid: 15044256
references.citation: Int J Hematol. 1999 Apr;69(3):186-95
references.pmid: 10222658
references.citation: Blood. 1987 Oct;70(4):926-31
references.pmid: 3115337
references.citation: Nature. 1984 Apr 26-May 2;308(5962):858-60
references.pmid: 6609313
references.citation: Leukemia. 1996 Sep;10(9):1453-5
references.pmid: 8751461